TST. J. Sindhu

T. J. Sindhu

*This is an algorithmically generated author record based on publicly available information.

T. J. Sindhu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Jainey Pj

    Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutical Chemistry, Deralakatte, Mangalore-575018, Karnataka, India

    6 shared publications
  • Zakiya Fathima C.

    Department of Pharmaceutical Chemistry, NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Nitte (Deemed to be University), Deralakatte, Mangaluru 575018, Karnataka, India

    6 shared publications
  • Shankar G. Alegaon

    Department of Pharmaceutical Chemistry, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research, Belagavi, Karnataka, India

    2 shared publications
  • Aswathi Jyothkumar

    Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutical Chemistry, Deralakatte, Mangalore-575018, Karnataka, India

    1 shared publication
  • B. C. Revanasiddappa

    Department of Pharmaceutical Chemistry, NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Nitte (Deemed to be University), Deralakatte, Mangaluru-575018, Karnataka, India

    1 shared publication
  • Bijo Mathew

    Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Amrita Health Science Campus, Kochi 682041, India

    1 shared publication

Latest Publications

  • Computational Design and Virtual Screening of Enumeration-Generated Benzothiazinone Derivatives as Cholinesterase Inhibitors Using Pharmacophore Modeling, Molecular Dynamics, DFT and ML-Based Predictive Modeling Analysis

    by T. Abhijith, Jainey P. James, T. J. Sindhu, C. Zakiya Fathima, Shankar G. Alegaon, Aswathi Jyothkumar, K. V. Gopika

    Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are key cholinergic targets implicated in Alzheimer’s disease (AD), and simultaneous modulation of these enzymes represents a promising strategy for addressing cholinergic dysfunction. In this study, a comprehensive computational approach was employed to investigate benzothiazinone derivatives as potential cholinesterase inhibitors. Molecular docking of a virtual library against AChE (PDB ID: 6O4W) identified several compounds with favorable binding affinities, among which compounds 1d, 1k, and 1a were prioritized based on their overall docking performance and binding interactions. Compound 1d exhibited a favorable AChE docking score of −9.441 kcal/mol, comparable to the reference drug donepezil. To assess their binding affinity to BChE, the selected compounds were docked with BChE (PDB ID: 5DYW). This resulted in docking scores of −8.796 kcal/mol for 1a, −8.859 kcal/mol for 1k, and −8.748 kcal/mol for 1d. Further Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) binding free-energy calculations confirmed these compounds’ strong binding, emphasizing the role of hydrophobic and van der Waals interactions in stabilizing the complexes. The stability of the selected ligand–protein complexes was subsequently evaluated through 100 ns molecular dynamics simulations, with compounds 1k and 1d exhibiting stable interactions within the respective binding sites. Pharmacophore modeling identified the AHRRR_1 hypothesis, comprising one hydrogen-bond acceptor, one hydrogen-bond donor, and three aromatic ring features, with a selectivity score of 1.985 and a survival score of 5.975. Density functional theory (DFT) calculations revealed favorable electronic characteristics, including suitable HOMO–LUMO distributions and charge-transfer properties. ADMET analysis indicated favorable pharmacokinetic profiles for several derivatives, while CatPred-based machine-learning analysis predicted inhibition constants (Ki) in the micromolar range, suggesting moderate to strong binding potential. Overall, the integrated AChE/BChE docking, MM-GBSA, molecular dynamics, pharmacophore modeling, DFT, ADMET, and machine-learning analyses highlight benzothiazinone derivatives, particularly 1d, 1k, and 1a, as promising cholinesterase-targeting candidates and provide valuable structural insights for the rational development of potential therapeutic agents against AD.

  • Open Access

    Rational Design of Pyrazole–Chalcone Congeners via Enumeration: Insights From Molecular Docking, MM‐GBSA, Pharmacophore Modelling, MD Simulations and DFT Calculations

    by Zakiya Fathima C., Jainey P. James, Srinivas Ganjipete, Parasuraman Pavadai, Sindhu T. J.

    Background: Monoamine oxidase‐B (MAO‐B) is a pivotal enzyme in the pathophysiology of Parkinson’s disease (PD), where its elevated activity accelerates dopamine catabolism, increases oxidative stress and contributes to the progressive loss of dopaminergic neurons. This study investigates the MAO‐B inhibitory potential of a series of pyrazole‐based chalcone derivatives using an integrated computational framework. Methods: A ligand library was generated through R‐group enumeration and screened for physicochemical suitability and pharmacokinetic compliance. Molecular docking against MAO‐B (PDB ID: 2BYB) was performed to evaluate binding affinity, which was further validated through MM‐GBSA binding free‐energy calculations. Pharmacophore modelling using Phase identified the key structural features governing MAO‐B inhibition. The top‐ranked complexes were subjected to molecular dynamics simulations to assess structural stability. Density functional theory (DFT) calculations were conducted to examine electronic reactivity, including HOMO–LUMO gaps and related quantum descriptors. Results: The designed ligands demonstrated favourable physicochemical and pharmacokinetic profiles. Docking studies indicated strong binding affinities, with several compounds outperforming the reference inhibitor deprenyl, consistent with MM‐GBSA predictions. Pharmacophore modelling revealed a five‐point AHHRR_1 hypothesis as the critical determinant of activity. Hydrophobic 3,5‐dimethyl substitutions on the pyrazole ring enhanced electron density and inhibitory potency, while the conjugated π‐system between pyrazole and phenyl moieties contributed to stabilised π–π interactions. Para‐substituted electron‐withdrawing groups on the phenyl ring further improved MAO‐B selectivity. Molecular dynamics simulations confirmed robust complex stability, with the 5b/2BYB complex exhibiting low RMSD, minimal residue fluctuations and persistent hydrogen‐bonding and hydrophobic contacts. DFT analysis revealed narrow HOMO–LUMO gaps, indicative of high electronic reactivity and strong binding propensity. Conclusion: Overall, this comprehensive computational investigation offers valuable insights for the rational design and optimisation of pyrazole–chalcone derivatives as promising MAO‐B inhibitors for PD therapy and supports their further in vitro and in vivo evaluation.

  • Open Access

    FOCUSED INSIGHTS INTO ALZHEIMER’S TREATMENT STRATEGIES: PHARMACOPHORE MODELLING, DFT STUDIES, MD SIMULATIONS AND SH-SY5Y NEUROPROTECTION OF NARINGIN

    by Sindhu T. J., Jainey P. James, Zakiya Fathima C., Rajalakshimi Vasudevan, Shankar G. Alegaon

    Objective: Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder involving oxidative stress, protein aggregation, and neurotransmitter imbalance. This study aimed to evaluate the neuroprotective potential of Drynaria quercifolia (DQ) phytoconstituents, particularly DQ5 (naringin), using in silico, in vitro, and pharmacological analyses for multitargeted AD therapy. Methods: Phytocompounds from DQ were analysed through molecular docking to assess binding affinities with AD-related targets, including acetylcholinesterase (AChE), monoamine oxidase-B (MAO-B), and peroxiredoxin-5 (Prdx-5). DQ5 (naringin) was further evaluated using molecular dynamics (MD) simulations and pharmacophore modelling. Density Functional Theory (DFT) was employed to assess molecular stability and reactivity. In vitro assays measured AChE, MAO-B, tyrosinase inhibition, and hydrogen peroxide scavenging. Neuroprotective effects were evaluated using MTT assay on SH-SY5Y neuroblastoma cells. Results: Molecular docking showed strong binding of DQ5 to AChE (-14.182 kcal/mol) and MAO-B (-13.393 kcal/mol). MD simulations confirmed complex stability. DQ5 (naringin) exhibits high stability in its gas-phase optimised structure, and its small HOMO-LUMO gap indicates it may be quite reactive, which could contribute to its biological activity. DQ5 inhibited AChE (IC₅₀ = 8.05±1.02 µg/ml) and 90% SH-SY5Y cell viability. Pharmacokinetic predictions supported favourable drug-likeness and safety profiles. Conclusion: DQ5 (naringin), a key metabolite from DQ, exhibits significant multitarget activity against AD-related enzymes and oxidative stress. The compound's pharmacological properties and neuroprotective effects highlight its promise as a natural therapeutic candidate for addressing multiple pathways involved in AD pathogenesis.


  • Mechanistic Insights into Thiazolidinones as Anticholinesterase Agents: 3D QSAR Pharmacophore Modeling, Molecular Docking, MD Simulations, and DFT Studies for Alzheimer’s Therapy

    by T. J. Sindhu, Jainey P. James, C. Zakiya Fathima, Bijo Mathew, Sunil Kumar

    Alertness toward multitarget, including acetylcholinesterase and butyrylcholinesterase, is crucial in addressing Alzheimer’s disease (AD). This study aims to explore the cholinesterase inhibitory potential of 37 thiazolidinone derivatives through computational techniques. In this study, in silico tools such as pharmacophore modeling, atom-based 3D QSAR study, molecular docking, binding free energy determination, molecular dynamics and density functional theory (DFT) studies were conducted by the software Schrodinger. Molecular docking against acetylcholinesterase (6O4W) displayed compound a6, with outstanding docking, complemented by MMGBSA for binding energy evaluation. Meanwhile, molecular dynamics (MD) simulations validated the stability of ligand-enzyme complexes and confirmed the stability of the a6/6O4W and a6/6EYF complexes. In DFT studies, based on the alpha_HOMO and alpha_LUMO energies, compound a6 was found to be electronically stable. Pharmacophore modeling and QSAR analysis identified structural features essential for inhibition. Pharmacophore modeling identified the five-feature hypotheses AAHHR_4 as the key structural feature for optimal inhibition. 3D-QSAR contour plot analysis was performed for the best compounds (in vitro and in silico studies) and compared with the weak compounds (in vitro studies). These findings emphasize the potential of thiazolidinone derivatives as potent acetylcholinesterase inhibitors. PASS tool predicted that all compounds would have anti-Alzheimer potential. Assessments of promiscuity showed that all thiazolidinones would be specific rather than promiscuous. These findings highlight the significance of computational studies in identifying promising compounds for treating AD.


  • Molecular Docking, Pharmacophore Modeling, 3D QSAR, Molecular Dynamics Simulation and MMPBSA Studies on Hydrazine-Linked Thiazole Analogues as MAO-B Inhibitors

    by C. Zakiya Fathima, Jainey P. James, Prarambh S. R. Dwivedi, T. J. Sindhu

    Background: Monoamine oxidase-B (MAO-B) is crucial in breaking down biogenic and dietary amines, with its dysregulation linked to Parkinson’s disease. Objective: This study aims to explore the MAO-B inhibitory potential of 34 hydrazine-linked thiazole derivatives through computational techniques. Methods: Molecular docking against MAO-B (2BYB) assessed binding affinity, complemented by MMGBSA for binding energy evaluation. Pharmacophore modeling and QSAR analysis identified structural features essential for inhibition, while molecular dynamics (MD) simulations validated the stability of ligand-MAO-B complexes. Results: Compound T18 exhibited outstanding binding affinity, while T9 showed the lowest. In vitro studies revealed that T2 had the weakest inhibitory potential, while T19 demonstrated the highest. Pharmacophore modeling identified the six-feature hypothesis ADHRRR_1 as the key structural feature for optimal inhibition. QSAR analysis provided insight into the importance of pharmacophoric features, including the electron-deficient 3-pyridine at N1 of hydrazine, which acts as an electron-withdrawing group that enhances interactions with the enzyme active site, making pyridine a valuable pharmacophore. Additionally, the electronegative fluorinated phenyl ring at C4 of thiazole enhances blood-brain barrier (BBB) permeability and selectivity for MAO-B. Notably, the methyl group on T19 acted as a hydrophobic feature, increasing electron density and boosting inhibitory activity. MD simulations confirmed the stability of the T18/2BYB and T19/2BYB complexes. Furthermore, T19 displayed superior CNS activity and BBB permeability, confirming the methyl group as crucial for enhanced action. Conclusion: These findings underscore the potential of hydrazine-linked thiazole derivatives as potent MAO-B inhibitors. Future in vivo studies are essential to explore their therapeutic benefits further.


  • Open Access

    INVESTIGATING MULTITARGET POTENTIAL OF MUCUNA PRURIENS AGAINST PARKINSON'S DISEASE: INSIGHTS FROM MOLECULAR DOCKING, MMGBSA, PHARMACOPHORE MODELLING, MD SIMULATIONS AND ADMET ANALYSIS

    by Zakiya Fathima C., Jainey P. James, Mahendra Gowdru Srinivasa, Sindhu T. J, Mariyam Jouhara B. M., B. C. Revanasiddappa, Sudeep D. Ghate

    Objective: Mucuna pruriens (Velvet beans) is a leguminous plant recognised in Vedic therapy as an anti-Parkinsonism agent. The plant is known as the natural reservoir for levodopa. The study aims to evaluate the multitarget inhibitory potency of active constituents present in Mucuna pruriens using in silico tools. Methods: The phytoconstituents present in Mucuna pruriens were retrieved from the IMPPAT database. The physicochemical and toxicity parameters of phytoconstituents were evaluated using Qikprop and ProTox-3. The inhibitory potential of phytoconstituents on the enzymes Monoamine Oxidase-B (MAO-B), Acetylcholinesterase (AChE), and Catechol-O-Methyltransferase (COMT) was evaluated using in silico techniques, including molecular docking, pharmacophore modelling, and molecular dynamics simulations, conducted with Schrödinger software programs. Results: The active constituents comply with Lipinski’s rule for drug-likeness. Further, the molecular docking studies revealed the phytoconstituent luteolin and acacetin showed promising multitargeted inhibitory properties. Especially luteolin (-11.504 kcal/mol) and acacetin (-10.620 kcal/mol) have obtained excellent docking scores with MAO-B, whereas the known drug levodopa showed a docking score of-8.501 kcal/mol. The pharmacophore modelling revealed that donor, acceptor, and aromatic features present in luteolin and acacetin are the essential pharmacophoric features accountable for biological activity. The simulation study generated the stability of the protein-ligand complex and found that luteolin showed a stable complex with MAO-B. Conclusion: Based on these findings, the result of the current study can be used to develop a novel luteolin-based drug for treating Parkinson’s disease with preferred structural modification. However, additional and more comprehensive research is required on this compound.